Dasatinib-Induced Pulmonary Arterial Hypertension Treated with Upfront Combination Therapy

Pulmonary arterial hypertension (PAH) is a rare complication of dasatinib that was approved as a first-line therapy for chronic myelocytic leukemia (CML). A 24-year-old man presenting dyspnea at rest and leg edema was admitted to our hospital. He had been diagnosed with CML and prescribed dasatinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishimori, Makoto, Honjo, Tomoyuki, Kaihotsu, Kenji, Sone, Naohiko, Yoshikawa, Sachiko, Imanishi, Junichi, Nakayama, Kazuhiko, Emoto, Noriaki, Iwahashi, Masanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985094/
https://www.ncbi.nlm.nih.gov/pubmed/29888010
http://dx.doi.org/10.1155/2018/3895197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985094/
https://www.ncbi.nlm.nih.gov/pubmed/29888010
http://dx.doi.org/10.1155/2018/3895197

Ejemplares similares